Pancreatic Cancer Research

Clinical trialPhase 1Active not recruiting

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

An Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of XL309 (ISM3091) as Single-Agent and Combination Therapy in Patients With Advanced Solid Tumors

Outcome
Ongoing
Phase
Phase 1
Status
Active not recruiting
Study type
Interventional
Start
3 April 2024
Expected end
31 December 2027
Enrollment
429 participants
Sites
13
Primary outcomes
Dose Escalation Stage: Incidence of TEAEs and SAEs; AEs Leading to Dose Modification, Discontinuation, or Death; and Laboratory Abnormalities; Dose Escalation Stage: Incidence of Dose-Limiting Toxicities (DLTs); Dose Escalation Stage: XL309 Exposure Over Time Measured as Area Under the Plasma Concentration Curve (AUC); Dose Escalation Stage: XL309 Maximum Plasma Concentration (Cmax); Dose Escalation Stage: XL309 Time to Cmax
Sponsor type
Industry
Results posted
No
Last update
6 November 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors.